Cannabinoids: A New Group of Agonists of PPARs

Abstract

Cannabinoids have been used medicinally and recreationally for thousands of years and their effects were proposed to occur mainly via activation of the G-protein-coupled receptor CB1/CB2 (cannabinoid receptor 1/2). Discovery of potent synthetic analogs of the natural cannabinoids as clinically useful drugs is the sustained aim of cannabinoid research. This demands that these new compounds be free of the psychotropic effects that connected with the recreational use of cannabinoids. In preclinical studies cannabinoids displayed many of the characteristics of nonsteroidal anti-inflammatory drugs (NSAIDs) and it seems to be free of unwanted side effects. An increasing number of therapeutic actions of cannabinoid are being reported that do not appear to be mediated by either CB1 or CB2, and recently nuclear receptor superfamily PPARs (peroxisome-proliferator-activated receptors) have been suggested as the target of certain cannabinoids. This review summarizes the evidence for cannabinoid activation on PPARs and possible associated remedial potentials.

References

1. R. Mechoulam and Y. Gaoni, “Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids,” Tetrahedron, vol. 21, no. 5, pp. 1223–1229, 1965. View at: Publisher Site | Google Scholar
2. A. C. Howlett, “Pharmacology of cannabinoid receptors,” Annual Review of Pharmacology Toxicology, vol. 35, pp. 607–634, 1995. View at: Google Scholar
3. R. Mechoulam, E. Fride, and V. Di Marzo, “Endocannabinoids,” European Journal of Pharmacology, vol. 359, no. 1, pp. 1–18, 1998. View at: Publisher Site | Google Scholar
4. S. A. Cook, J. A. Lowe, and B. R. Martin, “CB1 receptor antagonist precipitates withdrawal in mice exposed to $\Delta$9- tetrahydrocannabinol,” Journal of Pharmacology and Experimental Therapeutics, vol. 285, no. 3, pp. 1150–1156, 1998. View at: Google Scholar
5. T. Nadulski, F. Pragst, and G. Weinberg et al., “Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of thc verses standardized cannabis extract,” Therapeutic Drug Monitoring, vol. 27, no. 6, pp. 799–810, 2005. View at: Publisher Site | Google Scholar
6. R. G. Pertwee, “Pharmacology of cannabinoid CB1 and CB2 receptors,” Pharmacology and Therapeutic, vol. 74, pp. 129–180, 1997. View at: Google Scholar
7. B. R. Martin, D. R. Compton, and B. F. Thomas et al., “Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs,” Pharmacology Biochemistry and Behavior, vol. 40, no. 3, pp. 471–478, 1991. View at: Publisher Site | Google Scholar
8. W. A. Devane, A. Breuer, T. Sheskin, T. U. C. Jarbe, M. S. Eisen, and R. Mechoulam, “A novel probe for the cannabinoid receptor,” Journal of Medicinal Chemistry, vol. 35, no. 11, pp. 2065–2069, 1992. View at: Google Scholar
9. D. M. Lambert and C. J. Fowler, “The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications,” Journal of Medicinal Chemistry, vol. 48, no. 16, pp. 5059–5087, 2005. View at: Publisher Site | Google Scholar
10. K.-O. Jonsson, S. Vandevoorde, D. M. Lambert, G. Tiger, and C. J. Fowler, “Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide,” British Journal of Pharmacology, vol. 133, no. 8, pp. 1263–1275, 2001. View at: Google Scholar
11. A. C. Howlett, F. Barth, and T. I. Bonner et al., “International union of pharmacology. XXVII. Classification of cannabinoid receptors,” Pharmacological Reviews, vol. 54, no. 2, pp. 161–202, 2002. View at: Publisher Site | Google Scholar
12. J. L. Wiley and B. R. Martin, “Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes,” Chemistry and Physics of Lipids, vol. 121, no. 1-2, pp. 57–63, 2002. View at: Google Scholar
13. D. Smart and J. C. Jerman, “Anandamide: an endogenous activator of the vanilloid receptor,” Trends in Pharmacological Sciences, vol. 21, no. 4, p. 134, 2000. View at: Publisher Site | Google Scholar
14. A. Calignano, R. G. La, and D. Piomelli, “Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide,” European Journal of Pharmacology, vol. 419, no. 2-3, pp. 191–198, 2001. View at: Publisher Site | Google Scholar
15. V. Di Marzo, C. S. Breivogel, and Q. Tao et al., “Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain,” Neurochemical Research, vol. 75, no. 6, pp. 2434–2444, 2000. View at: Google Scholar
16. C. S. Breivogel, G. Griffin, V. Di Marzo, B. R. Martin, R. K. Razdan, A. M. Zimmer, A. Zimmer, and B. R. Martin, “Evidence for a new G protein-coupled cannabinoid receptor in mouse brain,” Molecular Pharmacology, vol. 60, no. 1, pp. 155–163, 2001. View at: Google Scholar
17. E. B. Russo, A. Burnett, B. Hall, and K. K. Parker, “Agonistic properties of cannabidiol at 5-HT1a receptors,” Neurochemical Research, vol. 30, no. 8, pp. 1037–1043, 2005. View at: Publisher Site | Google Scholar
18. S. S. Davies, A. V. Pontsler, and G. K. Marathe et al., “Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor $\gamma$ ligands and agonists,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16015–16023, 2001. View at: Publisher Site | Google Scholar
19. M. Gottlicher, E. Widmark, Q. Li, and J.-A. Gustafsson, “Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4653–4657, 1992. View at: Publisher Site | Google Scholar
20. K. Yu, W. Bayona, and C. B. Kallen et al., “Differential activation of peroxisome proliferator-activated receptors by eicosanoids,” Journal of Biological Chemistry, vol. 270, no. 41, pp. 23975–23983, 1995. View at: Publisher Site | Google Scholar
21. M. V. Chakravarthy, Z. Pan, and Y. Zhu et al., ““New” hepatic fat activates PPAR$\alpha$ to maintain glucose, lipid, and cholesterol homeostasis,” Cell Metabolism, vol. 1, no. 5, pp. 309–322, 2005. View at: Publisher Site | Google Scholar
22. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors $\alpha$ and $\delta$,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at: Publisher Site | Google Scholar
23. T. M. Willson, J. E. Cobb, and D. J. Cowan et al., “The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones,” Journal Medical Chemistry, vol. 39, pp. 665–668, 1996. View at: Google Scholar
24. W. R. Oliver Jr., J. L. Shenk, and M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, pp. 5306–5311, 2001. View at: Google Scholar
25. J. Fu, F. Oveisi, S. Gaetani, E. Lin, and D. Piomelli, “Oleoylethanolamide, an endogenous PPAR-$\alpha$ agonist, lowers body weight and hyperlipidemia in obese rats,” Neuropharmacology, vol. 48, no. 8 SPEC. ISS., pp. 1147–1153, 2005. View at: Publisher Site | Google Scholar
26. J. Fu, S. Gaetani, and F. Oveisi et al., “Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-$\alpha$,” Nature, vol. 425, no. 6953, pp. 90–93, 2003. View at: Google Scholar
27. M. Guzmàn, V. J. Lo, J. Fu, F. Oveisi, C. Blàzquez, and D. Piomelli, “Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-$\alpha$),” Journal of Biological Chemistry, vol. 279, no. 27, pp. 27849–27854, 2004. View at: Google Scholar
28. S. E. O'Sullivan, E. J. Tarling, A. J. Bennett, D. A. Kendall, and M. D. Randall, “Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma,” Biochemical and Biophysical Research Communications, vol. 337, no. 3, pp. 824–831, 2005. View at: Publisher Site | Google Scholar
29. R. B. Zurier, R. G. Rossetti, J. H. Lane, J. M. Goldberg, S. A. Hunter, and S. H. Burstein et al., “Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure,” Arthritis and Rheumatism, vol. 41, no. 1, pp. 163–170, 1998. View at: Publisher Site | Google Scholar
30. J. Liu, H. Li, S. H. Burstein, R. B. Zurier, and J. D. Chen, “Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid,” Molecular Pharmacology, vol. 63, pp. 983–992, 2003. View at: Google Scholar
31. F. Maingret, A. J. Patel, M. Lazdunski, and E. Honorè, “The endocannabinoid anandamide is a direct and selective blocker of the background K$+$ channel TASK-1,” EMBO Journal, vol. 20, no. 1-2, pp. 47–54, 2001. View at: Publisher Site | Google Scholar
32. V. Di Marzo, A. Fontana, and H. Cadas et al., “Formation and inactivation of endogenous cannabinoid anandanide in central neurons,” Nature, vol. 372, no. 6507, pp. 686–691, 1994. View at: Google Scholar
33. C. J. Fowler, G. Tiger, A. Ligresti, M. L. Lòpez-Rodrìguez, and V. Di Marzo, “Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis—a difficult issue to handle,” European Journal of Pharmacology, vol. 492, no. 1, pp. 1–11, 2004. View at: Publisher Site | Google Scholar
34. V. Di Marzo, T. Bisogno, P. L. De, D. Melck, and B. R. Martin, “Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids,” Current Medicinal Chemistry, vol. 6, no. 8, pp. 721–744, 1999. View at: Google Scholar
35. S. H. Burstein, R. G. Rossetti, B. Yagen, and R. B. Zurier, “Oxidative metabolism of anandamide,” Prostaglandins and Other Lipid Mediators, vol. 61, no. 1-2, pp. 29–41, 2000. View at: Publisher Site | Google Scholar
36. M. Bouaboula, S. Hilairet, J. Marchand, L. Fajas, G. Le Fur, and P. Casellas, “Anandamide induced PPAR$\gamma$ transcriptional activation and 3T3-L1 preadipocyte differentiation,” European Journal of Pharmacology, vol. 517, no. 3, pp. 174–181, 2005. View at: Publisher Site | Google Scholar
37. Y. Sun, S. P. H. Alexander, D. A. Kendall, and A. J. Bennett, “Cannabinoids and PPAR$\alpha$ signalling,” Biochemical Society Transactions, vol. 34, no. 6, pp. 1095–1097, 2006. View at: Publisher Site | Google Scholar
38. V. J. Lo, J. Fu, and G. Astarita et al., “The nuclear receptor peroxisome proliferator-activated receptor-$\alpha$ mediates the anti-inflammatory actions of palmitoylethanolamide,” Molecular Pharmacology, vol. 67, no. 1, pp. 15–19, 2005. View at: Publisher Site | Google Scholar
39. C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski, “Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor $\gamma$ independently of cannabinoid receptors 1 and 2,” Molecular Pharmacology, vol. 70, no. 1, pp. 101–111, 2006. View at: Publisher Site | Google Scholar
40. S. Vandevoorde and D. M. Lambert, “Focus on the three key enzymes hydrolysing endocannabinnoids as new drug targets,” Current Pharmaceutical Design, vol. 11, no. 20, pp. 2647–2668, 2005. View at: Publisher Site | Google Scholar
41. N. Ueda, K. Yamanaka, and S. Yamamoto, “Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance,” Journal of Biological Chemistry, vol. 276, no. 38, pp. 35552–35557, 2001. View at: Publisher Site | Google Scholar
42. J. Lengqvist, U. A. Mata De, and A.-C. Bergman et al., “Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor $\alpha$ ligand-binding domain,” Molecular and Cellular Proteomics, vol. 3, no. 7, pp. 692–703, 2004. View at: Google Scholar
43. D. Rueda, I. Galve-Roperh, A. Haro, and M. Guzman, “The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase,” Molecular Pharmacology, vol. 58, no. 4, pp. 814–820, 2000. View at: Google Scholar
44. L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “Kinase signaling cascades that modulate peroxisome proliferator-activated receptors,” Current Opinion in Cell Biology, vol. 17, no. 2, pp. 216–222, 2005. View at: Publisher Site | Google Scholar
45. R. G. Pertwee, “The pharmacology of cannabinoid receptors and their ligands: an overview,” International Journal of Obesity, vol. 30, suppl. 1, pp. S13–S18, 2006. View at: Publisher Site | Google Scholar

Copyright

Copyright © 2007 Yan Sun and Andy Bennett. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.